Meng-Ju Wu to Isocitrate Dehydrogenase
This is a "connection" page, showing publications Meng-Ju Wu has written about Isocitrate Dehydrogenase.
Connection Strength
1.485
-
Wu MJ, Kondo H, Kammula AV, Shi L, Xiao Y, Dhiab S, Xu Q, Slater CJ, Avila OI, Merritt J, Kato H, Kattel P, Sussman J, Gritti I, Eccleston J, Sun Y, Cho HM, Olander K, Katsuda T, Shi DD, Savani MR, Smith BC, Cleary JM, Mostoslavsky R, Vijay V, Kitagawa Y, Wakimoto H, Jenkins RW, Yates KB, Paik J, Tassinari A, Saatcioglu DH, Tron AE, Haas W, Cahill D, McBrayer SK, Manguso RT, Bardeesy N. Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity. Science. 2024 07 12; 385(6705):eadl6173.
Score: 0.835
-
Specht E, Pakanati L, Wu MJ, Jenkins RW, Effiom DN, Bardeesy N, Bernstein BE, Sade-Feldman M, Lian CG, Boland GM, Torlai Triglia E, Cohen S. Loss of tumor-infiltrating lymphocytes and poor response to immunotherapy in IDH GOF mutant melanoma. JCI Insight. 2026 Jun 08; 11(11).
Score: 0.236
-
Wu MJ, Shi L, Merritt J, Zhu AX, Bardeesy N. Biology of IDH mutant cholangiocarcinoma. Hepatology. 2022 05; 75(5):1322-1337.
Score: 0.178
-
Wu MJ, Shi L, Dubrot J, Merritt J, Vijay V, Wei TY, Kessler E, Olander KE, Adil R, Pankaj A, Tummala KS, Weeresekara V, Zhen Y, Wu Q, Luo M, Shen W, Garc?a-Beccaria M, Fern?ndez-Vaquero M, Hudson C, Ronseaux S, Sun Y, Saad-Berreta R, Jenkins RW, Wang T, Heikenw?lder M, Ferrone CR, Goyal L, Nicolay B, Deshpande V, Kohli RM, Zheng H, Manguso RT, Bardeesy N. Mutant IDH Inhibits IFN?-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma. Cancer Discov. 2022 03 01; 12(3):812-835.
Score: 0.177
-
Zhang Z, Liu YK, Luo Z, Wu MJ, Evans CN, Qu Z, Xue F, Wang Z, Stanciu L, Zhang ZY, Parkinson EI, Bardeesy N, Andy Tao W. Discovery of chirally dependent protein modifications by D- and L-2-hydroxyglutarates. Nat Chem. 2026 06; 18(6):1033-1041.
Score: 0.059